Business · 10/03/2026Updated: 10/16/2026 · 1 min read
FDA Sets Regulatory Review Period for AURORA EV-ICD Patent Extension
Summary
The US Food and Drug Administration (FDA) has set a regulatory review period for the patent extension of AURORA EV-ICD, a pacemaker developed by AURORA Corporation.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →